Genentech to Begin Second Phase 3 Trial
for Alzheimer's Therapy
AC Immune SA,
company focused on
that its partner
of Roche group, started a second Phase 3 clinical trial of the
Alzheimer's therapy crenezumab, an anti-Abeta antibody.
The new CREAD2 trial was set to recruit 750 patients
with prodromal or mild Alzheimer's disease. It complements
the current Phase 3 CREAD1 trial of 750 participants with
prodromal or mild Alzheimer's disease, expected to read out
Crenezumab was discovered by AC Immune
using its SupraAntigen technology platform and
out-licensed to Genentech in 2006 as a potential
therapy for Alzheimer's disease.
Read more at: http://bit.do/dkpcB
Novo Nordisk A/S announced
in March that Jakob Riis,
executive vice president, head
of North America Operations
and president of Novo Nordisk
Inc., resigned from the company.
Effective March 1, Doug
Langa, senior vice president
for Market Access, Novo
Nordisk Inc., was appointed
senior vice president, head of
North America Operations and
president of Novo Nordisk Inc.
He reports to Lars Fruergaard Jørgensen, president and CEO,
Novo Nordisk A/S.
Langa joined the company in 2011 as senior director, managed
markets. He previously was with GlaxoSmithKline
serving as senior director of payer marketing. Prior
to GSK, Langa spent the majority of his career at
Johnson & Johnson, where he held various roles.
Read more at: http://bit.do/dkozF
harmless by the
risk of cardiac
to a European
drugs (NSAIDs) are among the most commonly used drugs
worldwide and some, including ibuprofen, are available over
In a study of 28,947 patients in Denmark over a 10-year
period, use of any NSAID was associated with a 31 percent
increased risk of cardiac arrest. Diclofenac and ibuprofen
were associated with a 50 percent and 31 percent increased
risk, respectively. Naproxen, celecoxib, and rofecoxib were not
associated with the occurrence of cardiac arrest.
NSAIDs exert numerous effects on the
cardiovascular system, which could explain the
link with cardiac arrest.
Read more at: http://bit.do/dkpUE
Change in Novo Nordisk
Associated with Increased
Risk of Cardiac Arrest
to Compete with Pharma
its pric than
operat d the